RAAPID

The architecture is the pitch. The company describes neuro symbolic AI combining machine learning with an explicit clinical knowledge structure, positioned specifically against systems that rely on pattern matching alone, and reports 92 percent out of the box accuracy rising above 98 percent after coder validation. Whether the neuro symbolic characterization is technically distinctive or a naming choice cannot be verified from public materials, but the product does not function without models reading clinical documentation.

Coder validation is built into the workflow and the company is unusually precise about what it contributes, reporting accuracy of 92 percent before human review and above 98 percent after. Publishing both numbers rather than only the post review figure tells a buyer exactly how much work the human is doing, which is a more honest framing than most vendors offer. The company markets an autonomous platform while describing coder validation as the step that produces final accuracy, and a buyer should read the autonomy language against that.

The central claim is explainability and it is described concretely: every suggested hierarchical condition category code links to specific MEAT based clinical evidence, producing what the company calls a Glass Box transparent and explainable audit trail, explicitly contrasted with systems that cannot articulate the clinical reasoning behind a suggestion. MEAT is the documentation standard CMS auditors apply, so tying output to it is substantive rather than decorative. Model architecture and independent validation of the accuracy figures are not published.

Claims are specific and quantified but entirely vendor reported with no independent validation located. Published figures include 92 percent out of the box accuracy rising above 98 percent with coder validation, 60 to 80 percent reduction in manual review burden, and 3 to 10 times return on investment. The company also asserts industry accuracy of 20 to 30 percent as its comparison baseline, which is a striking claim about competitors that no cited source supports. Backing from a major corporate venture arm is a diligence signal of a limited kind. Founded in 2022, so there is no longitudinal track record.

No published PHI framework or data governance disclosure was located. The platform processes complete clinical documentation across health plan and health system populations for coding purposes, which is a broad and sensitive data surface.

No HIPAA or BAA commitment was located, though business associate status is structurally required for a vendor performing chart review on behalf of health plans and providers.

No SOC 2, HITRUST, or ISO 27001 attestation was located, and no trust center was found.

No FDA pathway applies, but this vendor is built around a specific regulatory regime and that is the point of the product. CMS risk adjustment rules govern here, particularly Risk Adjustment Data Validation audits, where a plan must produce clinical documentation meeting MEAT criteria to support every submitted diagnosis code. The company positions its evidence linking explicitly as defense against RADV clawbacks and covers RADV audit workflows as a first class use case. Building the product around the audit standard rather than treating compliance as an afterthought is the right orientation for this category.

No formal governance program or bias evaluation was located, but the explainability architecture functions as a governance control in practice, since a code that must be traced to specific documented clinical evidence cannot be generated from statistical association alone. That structurally constrains one failure mode this category is prone to. No analysis addresses whether performance varies by documentation quality, specialty, or population, which is the live equity question when documentation density differs across patient groups.

No named EHR integrations, standards support, or data ingestion detail were located. The platform operates on clinical documentation for retrospective and prospective review, which implies chart access, but nothing about how that access is established is published.

No hosting, tenancy, or data residency disclosure was located.

No published pricing. The company frames economics as 3 to 10 times return on investment with 40 percent lower cost, which describes a claimed outcome rather than a price, and gives a buyer nothing to model against without knowing the baseline.

Coverage spans the full risk adjustment workflow rather than one phase, including prospective documentation improvement, retrospective coding recovery, and RADV audit defense, which is broader than competitors specializing at one end. Buyer types span health plans, health systems, at risk provider organizations, medical coding companies, and health technology companies. Program coverage centers on Medicare Advantage, ACA, and at risk arrangements. Not a clinical product and should not be evaluated as one.